摘要
目的探讨阿帕替尼联合同步放化疗治疗中晚期宫颈癌的临床疗效及不良反应。方法选取2017年2月~2019年2月40例中晚期宫颈癌(ⅡB~ⅢB期),随机分为放化疗联合阿帕替尼组(试验组)20例、放化疗组(对照组)20例。试验组予以同步放化疗联合阿帕替尼治疗,对照组予以同步放化疗。观察患者的临床疗效及毒副反应。结果放疗后3个月复查,试验组患者治疗有效率为80%,对照组为50%,试验组更高,差异有统计学意义(χ^2=3.956,P<0.05)。两组治疗过程中出现的不良反应主要有腹泻、手足综合征、皮疹、高血压、骨髓抑制、蛋白尿等,试验组不良反应发生率与对照组比较,差异无统计学意义(P>0.05)。结论与同步放化疗相比,中晚期宫颈癌阿帕替尼联合同步放化疗治疗效果好,毒副反应可耐受。
Objective To explore the clinical efficacy and adverse reactions of apatinib combined with concurrent radiochemotherapy in the treatment of advanced cervical cancer.Methods From February 2017 to February 2019,forty cases of mid-advanced cervical cancer(stageⅡB~ⅢB)in our department were randomly divided into 20 cases in the radiochemotherapy combined with apatinib group(experimental group)and 20 cases in the radiochemotherapy group(control group).The experimental group was given concurrent chemoradiotherapy combined with apatinib,and the control group was given simultaneous chemoradiotherapy.The clinical effect and side effects were observed.Results Rechecked 3 months after radiotherapy,the treatment effective rate of patients in the experimental group was 80%,and that in the control group was 50%.The results showed that the experimental group was higher and there was a significant difference(χ^2=3.956,P<0.05).The side effects during the treatment of the two groups were mainly diarrhea,hand and foot syndrome,rash,hypertension,bone marrow suppression,proteinuria,etc.Compared with the control group,the incidence of adverse reactions in the test group was not statistically significant(P>0.05).Conclusion Compared with concurrent radiochemotherapy,apatinib combined with concurrent radiochemotherapy for cervical cancer has good effect and tolerable toxic side effects.
作者
任园园
杨春华
REN Yuan-yuan;YANG Chun-hua(Department of radiation oncology,the affiliated hospital of Xuzhou Medical University,Xuzhou 221000,China)
出处
《中国处方药》
2020年第11期120-122,共3页
Journal of China Prescription Drug
关键词
宫颈癌
阿帕替尼
放化疗
中晚期
Cervical cancer
Apatinib
Radiotherapy and chemotherapy
Mid-advanced stage
